Claims
- 1. A viral vector conjugated to a microparticle, wherein the viral vector comprises a polynucleotide encoding a heterologous immunogenic polypeptide.
- 2. The viral vector of claim 1, which comprises a virus particle, a virus-like particle or a virus replicon particle.
- 3. The viral vector of claim 1, which is derived from a virus that enters cells via receptor mediated endocytosis.
- 4. The viral vector of claim 3, wherein the virus is a rhinovirus, adenovirus, enterovirus, poliovirus, coxsackie virus, echovirus, cardiovirus, hepatovirus, alphavirus, rubellavirus, flavivirus, pestivirus, hepatitis C virus, orthomyxovirus, bunyavirus, hantavirus, or nairovirus.
- 5. The viral vector of claim 1, wherein the viral vector is derived from a virus that enters cells via pH independent membrane fusion.
- 6. The viral vector of claim 5, wherein the virus is a parainfluenza virus, mumps virus, measles virus, respiratory syncytial virus, retrovirus, herpes virus or pox virus.
- 7. The viral vector of claim 1, wherein the microparticle has a characteristic length of about 0.5 μm to about 20 μm.
- 8. The viral vector of claim 1, wherein the microparticle comprises a wall-forming material selected from the group consisting of poly(lacto-co-glycolide) (PLG), poly(lactide), poly(glycolide), poly(caprolactone), poly(hydroxybutyrate) and copolymers thereof.
- 9. The viral vector of claim 1, wherein the microparticle comprises a positively charged surface.
- 10. The viral vector of claim 1, wherein the microparticle comprises a cationic lipid, a polymer of a natural or synthetic monomer, an anonic surfactant or a combination thereof.
- 11. The viral vector of claim 1, wherein the microparticle further comprises polyvinyl alcohol, polyvinyl pyrilidone, carboxymethyl cellulose, gelatin, polyoxyethylene(20) sorbitan monolaurate or a combination thereof.
- 12. The viral vector of claim 1, which is conjugated to the microparticle by surface adsorption.
- 13. The viral vector of claim 1, which is conjugated to the microparticle by covalent interaction.
- 14. The vital vector of claim 1, which is conjugated to the microparticle by non-covalent interaction.
- 15. The viral vector of claim 1, which is conjugated to the microparticle by ionic interaction.
- 16. The viral vector of claim 1, wherein the polypeptide i, an antigen associated with cancer, autoimmune disease, or infectious disease.
- 17. The viral vector of claim 1, wherein the polypeptide is an antigen associated with M. tuberculosis.
- 18. A method of producing a microparticle for delivery of a viral vector comprising conjugating a viral vector to a microparticle, wherein the microparticle is formed by dissolving a polymer in a solvent solution, emulsifying the solution, and hardening the microparticles formed by the solution.
- 19. A microparticle produced by the method of claim 18.
- 20. A method of stimulating cytokine production or proliferation of T cells specific for an antigen, the method comprising contacting the antigen-specific T cells with a vital vector of claim 1, wherein the heterologous immunogenic polypeptide comprises the antigen to which the T cells are specific.
- 21. A method for delivering a polynucleotide to a cell comprising contacting the cell with a viral vector of claim 1.
- 22. The method of claim 21, wherein the cell is an antigen-presenting cell.
- 23. The method of claim 22, wherein the antigen-presenting cell is a dendritic cell.
- 24. The method of claim 21, wherein the contacting occurs ex vivo.
- 25. The method of claim 21, wherein the contacting occurs in vivo.
- 26. A vaccine comprising the viral vector of claim 1.
- 27. The vaccine of claim 26, further comprising an adjuvant.
- 28. A method for delivering a polynucleotide to a subject comprising administering to the subject a vaccine of claim 26.
- 29. A method of stimulating an immune response in a subject comprising administering a vaccine of claim 26 to the subject.
Parent Case Info
[0001] This application claims the benefit of priority to U.S. provisional application Nos. 60/260,164, filed Jan. 5, 2001, and 60/333,701, filed Nov. 27, 2001, the entire contents of each of which are incorporate by reference herein.
Provisional Applications (2)
|
Number |
Date |
Country |
|
60260164 |
Jan 2001 |
US |
|
60333701 |
Nov 2001 |
US |